Annual revenue:
$680.50M+$218.33M(+47.24%)Summary
- As of today (April 18, 2025), ITCI annual revenue is $680.50 million, with the most recent change of +$218.33 million (+47.24%) on December 31, 2024.
- During the last 3 years, ITCI annual revenue has risen by +$598.79 million (+732.85%).
- ITCI annual revenue is now at all-time high.
Performance
ITCI Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly revenue:
$199.22M+$24.06M(+13.74%)Summary
- As of today (April 18, 2025), ITCI quarterly revenue is $199.22 million, with the most recent change of +$24.06 million (+13.74%) on December 1, 2024.
- Over the past year, ITCI quarterly revenue has increased by +$24.06 million (+13.74%).
- ITCI quarterly revenue is now at all-time high.
Performance
ITCI Quarterly revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM revenue:
$680.50M+$67.72M(+11.05%)Summary
- As of today (April 18, 2025), ITCI TTM revenue is $680.50 million, with the most recent change of +$67.72 million (+11.05%) on December 1, 2024.
- Over the past year, ITCI TTM revenue has increased by +$67.72 million (+11.05%).
- ITCI TTM revenue is now at all-time high.
Performance
ITCI TTM revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
ITCI Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +47.2% | +13.7% | +11.1% |
| 3 y3 years | +732.9% | +58.4% | +62.8% |
| 5 y5 years | - | +58.4% | +62.8% |
ITCI Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +732.9% | at high | +473.2% | at high | +574.5% |
| 5 y | 5-year | at high | +2920.3% | at high | >+9999.0% | at high | >+9999.0% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high | >+9999.0% |
Intra-Cellular Therapies Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $680.50M(+47.2%) | - | - |
| Dec 2024 | - | $199.22M(+13.7%) | $680.50M(+11.1%) |
| Sep 2024 | - | $175.16M(+8.6%) | $612.78M(+8.8%) |
| Jun 2024 | - | $161.28M(+11.3%) | $563.43M(+10.0%) |
| Mar 2024 | - | $144.84M(+10.1%) | $512.29M(+10.8%) |
| Dec 2023 | $462.18M(+85.5%) | $131.51M(+4.5%) | $462.18M(+10.5%) |
| Sep 2023 | - | $125.81M(+14.2%) | $418.10M(+14.8%) |
| Jun 2023 | - | $110.13M(+16.3%) | $364.16M(+17.8%) |
| Mar 2023 | - | $94.73M(+8.3%) | $309.11M(+24.1%) |
| Dec 2022 | $249.13M(+204.9%) | $87.43M(+21.7%) | $249.13M(+33.1%) |
| Sep 2022 | - | $71.87M(+30.5%) | $187.22M(+36.7%) |
| Jun 2022 | - | $55.07M(+58.5%) | $136.95M(+35.8%) |
| Mar 2022 | - | $34.76M(+36.2%) | $100.88M(+23.5%) |
| Dec 2021 | $81.71M(+262.6%) | $25.52M(+18.1%) | $81.71M(+19.1%) |
| Sep 2021 | - | $21.61M(+13.7%) | $68.60M(+26.2%) |
| Jun 2021 | - | $19.01M(+22.0%) | $54.36M(+46.0%) |
| Mar 2021 | - | $15.58M(+25.6%) | $37.23M(+65.2%) |
| Dec 2020 | $22.53M | $12.40M(+68.3%) | $22.53M(+122.5%) |
| Sep 2020 | - | $7.37M(+292.8%) | $10.13M(+267.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2020 | - | $1.88M(+112.6%) | $2.76M(+212.6%) |
| Mar 2020 | - | $882.50K(>+9900.0%) | $882.50K(+258.9%) |
| Dec 2017 | $245.80K(-25.7%) | $5100.00(-83.4%) | $245.90K(-27.4%) |
| Sep 2017 | - | $30.80K(-73.1%) | $338.70K(+8.5%) |
| Jun 2017 | - | $114.70K(+20.4%) | $312.30K(-26.7%) |
| Mar 2017 | - | $95.30K(-2.7%) | $426.00K(+28.8%) |
| Dec 2016 | $330.70K(+977.2%) | $97.90K(+2125.0%) | $330.70K(+63.1%) |
| Sep 2016 | - | $4400.00(-98.1%) | $202.80K(+2.2%) |
| Jun 2016 | - | $228.40K(-861.3%) | $198.40K(+546.3%) |
| Dec 2015 | $30.70K(-94.4%) | -$30.00K(-152.3%) | $30.70K(-86.1%) |
| Jun 2015 | - | $57.40K(+1639.4%) | $221.20K(-42.2%) |
| Mar 2015 | - | $3300.00(-90.9%) | $383.00K(-30.0%) |
| Dec 2014 | $547.50K(-80.0%) | $36.10K(-71.0%) | $547.50K(-59.1%) |
| Sep 2014 | - | $124.40K(-43.2%) | $1.34M(-28.9%) |
| Jun 2014 | - | $219.20K(+30.6%) | $1.88M(+13.2%) |
| Mar 2014 | - | $167.80K(-79.7%) | $1.66M(+11.2%) |
| Dec 2013 | $2.74M(-12.2%) | $827.50K(+23.9%) | $1.50M(+123.9%) |
| Sep 2013 | - | $668.00K | $668.00K |
| Dec 2012 | $3.12M | - | - |
FAQ
- What is Intra-Cellular Therapies annual revenue?
- What is the all time high annual revenue for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies annual revenue year-on-year change?
- What is Intra-Cellular Therapies quarterly revenue?
- What is the all time high quarterly revenue for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies quarterly revenue year-on-year change?
- What is Intra-Cellular Therapies TTM revenue?
- What is the all time high TTM revenue for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies TTM revenue year-on-year change?
What is Intra-Cellular Therapies annual revenue?
The current annual revenue of ITCI is $680.50M
What is the all time high annual revenue for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high annual revenue is $680.50M
What is Intra-Cellular Therapies annual revenue year-on-year change?
Over the past year, ITCI annual revenue has changed by +$218.33M (+47.24%)
What is Intra-Cellular Therapies quarterly revenue?
The current quarterly revenue of ITCI is $199.22M
What is the all time high quarterly revenue for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high quarterly revenue is $199.22M
What is Intra-Cellular Therapies quarterly revenue year-on-year change?
Over the past year, ITCI quarterly revenue has changed by +$24.06M (+13.74%)
What is Intra-Cellular Therapies TTM revenue?
The current TTM revenue of ITCI is $680.50M
What is the all time high TTM revenue for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high TTM revenue is $680.50M
What is Intra-Cellular Therapies TTM revenue year-on-year change?
Over the past year, ITCI TTM revenue has changed by +$67.72M (+11.05%)